Biogen (BIIB) : 18 analysts are covering Biogen (BIIB) and their average rating on the stock is 1.75, which is read as a Buy. 10 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. Biogen (BIIB) also receives 2 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 6 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Biogen (BIIB) : The highest short term price target forecast on Biogen (BIIB) is $450 and the lowest target price is $268. A total of 15 equity analysts are currently covering the company. The average price of all the analysts is $352.4 with a standard deviation of $52.77.
For the current week, the company shares have a recommendation consensus of Buy.
Biogen (NASDAQ:BIIB): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $253.78 and $251.29 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $254.85. The buying momentum continued till the end and the stock did not give up its gains. It closed at $253.36, notching a gain of 0.32% for the day. The total traded volume was 1,175,107 . The stock had closed at $252.54 on the previous day.
Biogen Inc., formerly Biogen Idec Inc., is a global biopharmaceutical company. The Company is focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. The Company develops, manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Companys marketed products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, FAMPYRA for multiple sclerosis (MS), ALPROLIX for hemophilia B, and ELOCTATE for hemophilia A, among others. It also collaborates on the development and commercialization of RITUXAN (rituximab), which is a monoclonal antibody for the treatment of non-Hodgkins lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA, which is for the treatment of chronic lymphocytic leukemia.